Xeligekimab

赛立奇单抗

Report date: 2026/02/13 20:01:31

Base Information

Drug NameXeligekimab
Drug Alias Name金立希GR-1501
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisAxial Spondyloarthritis +[6] 
Global Approved IndicationsPlaque psoriasis
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryMainland China
Original Approved Date2024/08/20
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenrix (Shanghai) Biopharmaceutical Co LtdChongqing Genrix Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTongji Hospital Of Tongji Medical College, Huazhong University Of Science And TechnologyChongqing Genrix Biopharmaceutical Co LtdGenrix (Shanghai) Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisAxial Spondyloarthritis +[5] 
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A